A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

INTRODUCTION

  • Org Study ID: SGNB6A-001
  • Secondary ID: N/A
  • NTC ID: NCT04389632
  • Sponsor: Seagen Inc.

BRIEF SUMMARY

This trial will look at a drug called SGN-B6A to find out whether it is safe for people who have solid tumors. It will study SGN-B6A to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SGN-B6A works to treat solid tumors.

The study will have two parts. Part A of the study will find out how much SGN-B6A should be given to participants. Part B will use the dose found in Part A to find out how safe SGN-B6A is and if it works to treat solid tumors.

  • Overall Status
    Recruiting
  • Start Date
    June 8, 2020
  • Phase
    Phase 1
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Number of participants with adverse events (AEs)

Primary Outcome 1 - Timeframe: Through 30-37 days following last dose of SGN-B6A; up to 3 years

Primary Outcome 2 - Measure: Number of patients with laboratory abnormalities

Primary Outcome 2 - Timeframe: Through 30-37 days following last dose of SGN-B6A; up to 3 years

Primary Outcome 3 - Measure: Number of participants with dose-limiting toxicities (DLTs)

Primary Outcome 3 - Timeframe: Through 30-37 days following last dose of SGN-B6A; up to 3 years

CONDITION

  • Carcinoma
  • Non-Small Cell Lung
  • Squamous Cell Carcinoma of Head and Neck
  • HER2 Negative Breast Neoplasms
  • Esophageal Squamous Cell Carcinoma
  • Esophageal Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Ovarian Neoplasms
  • Cutaneous Squamous Cell Cancer
  • Exocrine Pancreatic Adenocarcinoma
  • Urinary Bladder Neoplasms
  • Uterine Cervical Neoplasms
  • Stomach Neoplasms

ELIGIBILITY

Inclusion Criteria:
Disease indication
Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on study part). Participants must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies and should have no appropriate standard-of-care therapeutic option.

- Non-small cell lung cancer (NSCLC)

- Head and neck squamous cell cancer (HNSCC)

- Advanced HER2-negative breast cancer

- Esophageal squamous cell carcinoma (ESCC)

- Esophageal/Gastro-esophageal junction adenocarcinoma (EAC/GEJ)

- Cutaneous squamous cell cancer (cSCC)

- Exocrine pancreatic adenocarcinoma

- Bladder cancer

- Cervical cancer

- Gastric cancer

- High grade serous ovarian cancer (HGSOC)
Participants enrolled in the following study parts should have a tumor site accessible for biopsy and agree to biopsy as follows:
Disease-specific expansion cohorts, participant 16 onwards: pretreatment biopsy

- Biology expansion cohort: pretreatment biopsy and on-treatment (Cycle 1) biopsy

- An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

- Measurable disease per the RECIST v1.1 at baseline
Exclusion Criteria
History of another malignancy within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they:
are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment,

- have no new or enlarging brain metastases, and

- are off of corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to first dose of study drug.

- Carcinomatous meningitis

- Previous receipt of an MMAE-containing agent or an agent targeting integrin beta-6

- Pre-existing neuropathy Grade 2 or greater per the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)
Any uncontrolled Grade 3 or higher (per NCI CTCAE v5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of SGN-B6A.
Routine antimicrobial prophylaxis is permitted

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Natalya Nazarenko, MD

Role: Study Director

Affiliation: Seagen Inc.

Overall Contact

Name: Natalya Nazarenko, MD

Phone: 866-333-7436

Email: clinicaltrials@seagen.com

LOCATION

Facility Status Contact
Facility: Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215
United States
Status: Recruiting Contact: Contact
Taylor Burns

tburns4@bidmc.harvard.edu
Facility: Dana Farber Cancer Institute
Boston, Massachusetts 02215
United States
Status: Recruiting Contact: Principal Investigator
Bruno Bockorny

MaryK_Liebers@DFCI.HARVARD.EDU
Facility: Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada 89169
United States
Status: Recruiting Contact: Contact
Mary Liebers

Illya_Dixon@dfci.harvard.edu
Facility: Case Western Reserve University / University Hospitals Cleveland Medical Center
Cleveland, Ohio 44106
United States
Status: Recruiting Contact: Contact
Illya Dixon

edwin.kingsley@usoncology.com
Facility: Providence Portland Medical Center
Portland, Oregon 97213
United States
Status: Recruiting Contact: Principal Investigator
Kartik Sehgal

Megan.Magdinec@UHhospitals.org
Facility: MD Anderson Cancer Center / University of Texas
Houston, Texas 77030
United States
Status: Recruiting Contact: Contact
Edwin Kingsley

CanClinRsrchStudies@providence.org
Facility: South Texas Accelerated Research Therapeutics
San Antonio, Texas 78229
United States
Status: Recruiting Contact: Principal Investigator
Edwin Kingsley

RKhan@mdanderson.org
Facility: Institut Gustave Roussy
Villejuif Cedex, 94805
France
Status: Recruiting Contact: Contact
Megan Magdinec

isabel.jimenez@startsa.com
Facility: Hospital Universitario Vall d'Hebron
Barcelona, 08035
Spain
Status: Recruiting Contact: Principal Investigator
Afshin Dowlati

Facility: Hospital Universitario HM Sanchinarro
Madrid, 28050
Spain
Status: Recruiting Contact: Contact
Providence Cancer Institute

Facility: University Hospital Lausanne CHUV
Lausanne, 1011
Switzerland
Status: Recruiting Contact: Principal Investigator
Rachel Sanborn

Facility: The Royal Marsden Hospital (Surrey)
Sutton, SM2 5PT
United Kingdom
Status: Recruiting Contact: Contact
Rabia Khan